CLNN News and Press, Clene Inc. From 06/29/23

2023-06-29 13:20:47 ET Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure. Today, we’re exploring the territory of cheap stocks trading under $1. What are Penny Stocks? Penny stocks typicall...

Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks of patient follow-up SALT LAKE CITY, June 26, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its...

Clene (NASDAQ: CLNN) , along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, recently announced the pricing of an underwritten pub...

Investment led by Vivo Capital with participation from SymBiosis, Acuta Capital Partners, AIGH Capital, Serrado Capital LLC, and other new biotech investors, with support from existing insiders $40 million underwritten public offering with up to an ad...

2023-06-16 10:08:10 ET Gainers: Oncorus ( ONCR ) +264% . Microbot Medical ( MBOT ) +24% . NeuBase Therapeutics ( NBSE ) +19% . Community Health Systems ( CYH ) +8% . Homology Medicines ( FIXX ) +4% . Losers: Panbela Therap...

2023-06-16 08:13:05 ET Panbela Therapeutics ( PBLA ) -31% . Clene ( CLNN ) -28% prices $40M public offering. Applied UV ( AUVI ) -27% . EdtechX Holdings Acquisition II ( EDTX ) -13% . Creative Medical Technology Holdings ( CELZ ) -...

SALT LAKE CITY, June 16, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease...

2023-06-15 17:24:45 ET Clene ( NASDAQ: CLNN ) intends to offer and sell common stock and warrants to purchase shares of common stock in a public offering, the company said Thursday. The shares of common stock and the accompanying warrants will be issued separately but ca...

SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease...

CNM-Au8 ® treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) Clene plans to discuss the totality of the survival and time-to-event results from the full CNM-Au8 clinical data set, including the plasma ...